Research Paper Volume 14, Issue 11 pp 4673—4698

CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma


Figure 1. Pathological and clinical prognostic analyses of CXCR4, EMT-and CSC-related protein expressions in epithelial ovarian cancer patients. (A) Expressions of CXCR4 and E-cadherin, N-cadherin, CD133, and NANOG in EOC and benign epithelial ovarian tumour tissues were analysed by immunohistochemistry (IHC) staining with the indicated antibody against each protein examined. Notably, presence of CXCR4 expression is in epithelial ovarian cancer (EOC) tissues (mainly located in cytoplasm), but absence of CXCR4 expression in benign epithelial ovarian tumour tissues. E-cadherin expression was higher in CXCR4-negative EOC tissues than in CXCR4-positive samples. Tumour cells in the CXCR4-negative section did not express N-cadherin or vimentin, whereas some tumour cells in the CXCR4-positive section expressed vimentin, snail, CD44, CD133 and NANOG. (BE) Kaplan–Meier survival curve analyses of the association between survival probability and CXCR4, E-cadherin, CD133 and NANOG expression using the log rank test E-cadherin (B); CXCR4 (C), CD133 (D), NONOG (E) expression.